Cargando…
The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. Th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234134/ https://www.ncbi.nlm.nih.gov/pubmed/37254497 http://dx.doi.org/10.1080/21645515.2023.2212568 |
_version_ | 1785052415951634432 |
---|---|
author | Sarkar, Aparajita Omar, Sara Alshareef, Aya Fanous, Kareem Sarker, Shaunak Alroobi, Hasan Zamir, Fahad Yousef, Mahmoud Zakaria, Dalia |
author_facet | Sarkar, Aparajita Omar, Sara Alshareef, Aya Fanous, Kareem Sarker, Shaunak Alroobi, Hasan Zamir, Fahad Yousef, Mahmoud Zakaria, Dalia |
author_sort | Sarkar, Aparajita |
collection | PubMed |
description | The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications. |
format | Online Article Text |
id | pubmed-10234134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-102341342023-06-02 The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review Sarkar, Aparajita Omar, Sara Alshareef, Aya Fanous, Kareem Sarker, Shaunak Alroobi, Hasan Zamir, Fahad Yousef, Mahmoud Zakaria, Dalia Hum Vaccin Immunother Coronavirus The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications. Taylor & Francis 2023-05-30 /pmc/articles/PMC10234134/ /pubmed/37254497 http://dx.doi.org/10.1080/21645515.2023.2212568 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Coronavirus Sarkar, Aparajita Omar, Sara Alshareef, Aya Fanous, Kareem Sarker, Shaunak Alroobi, Hasan Zamir, Fahad Yousef, Mahmoud Zakaria, Dalia The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title_full | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title_fullStr | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title_full_unstemmed | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title_short | The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review |
title_sort | relative prevalence of the omicron variant within sars-cov-2 infected cohorts in different countries: a systematic review |
topic | Coronavirus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234134/ https://www.ncbi.nlm.nih.gov/pubmed/37254497 http://dx.doi.org/10.1080/21645515.2023.2212568 |
work_keys_str_mv | AT sarkaraparajita therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT omarsara therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT alshareefaya therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT fanouskareem therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT sarkershaunak therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT alroobihasan therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT zamirfahad therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT yousefmahmoud therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT zakariadalia therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT sarkaraparajita relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT omarsara relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT alshareefaya relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT fanouskareem relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT sarkershaunak relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT alroobihasan relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT zamirfahad relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT yousefmahmoud relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview AT zakariadalia relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview |